# Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations

> **NCT02643329** · PHASE1 · COMPLETED · sponsor: **Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited** · enrollment: 17 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BF-Gliclazide Tablet 80mg
- **DRUG:** Diamicron 80mg Tablet

## Key facts

- **NCT ID:** NCT02643329
- **Lead sponsor:** Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-03
- **Final completion:** 2016-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2016-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02643329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02643329, "Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02643329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*